BRISBANE, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing
medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will be a speaker
and panelist during the International Society for Neglected Tropical Diseases (ISNTD) Chagas conference.
ISNTD Chagas will take place on Thursday, April 6, 2017, at the Kimpton Hotel Palomar in
Washington, D.C.
Dr. Durrant will join Jeffrey Moe, PhD, of the Duke Global Health Institute, Anne Marie Finley of the Biotech Policy Group, and
Cecilia Inés Centurión of the Chagas Disease Alliance in a session to discuss how public policy can support the development of
medicines for neglected tropical diseases.
“Chagas is a neglected tropical disease in the U.S. affecting approximately 300,000 underserved people, and the inaugural ISNTD
Chagas conference will bring together experts and stakeholders from across the spectrum in a groundbreaking gathering in our
nation’s capital,” said Dr. Durrant. “Chagas needs more attention, and with the necessary ingredients of dedicated stakeholders,
enlightened public policy and patient care including approved medicines, we can hopefully make a difference. We look forward to
building collaborative dialogue and understanding to improve the foundation from which to help these neglected patients.”
ISNTD Chagas aims to bring together the Chagas R&D community, patient advocates, civic groups, and policymakers to further
efforts to combat this neglected global health issue. For more information about the conference, please visit www.isntdchagas.com.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients
with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are
benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and
ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as chronic myelomonocytic
leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 mike.cole@mzgroup.us Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 media@kalobios.com
